% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AlShweiki:154327,
      author       = {Al Shweiki, Mhd Rami and Oeckl, Patrick and Pachollek,
                      Adrian and Steinacker, Petra and Barschke, Peggy and
                      Halbgebauer, Steffen and Anderl-Straub, Sarah and Lewerenz,
                      Jan and Ludolph, Albert C and Bernhard Landwehrmeyer, Georg
                      and Otto, Markus},
      title        = {{C}erebrospinal {F}luid {L}evels of
                      {P}rodynorphin-{D}erived {P}eptides are {D}ecreased in
                      {H}untington's {D}isease.},
      journal      = {Movement disorders},
      volume       = {36},
      number       = {2},
      issn         = {1531-8257},
      address      = {New York, NY},
      publisher    = {Wiley},
      reportid     = {DZNE-2021-00181},
      pages        = {492 - 497},
      year         = {2021},
      note         = {ISSN 1531-8257 not unique: **3 hits**.},
      abstract     = {Huntington's disease (HD) is a devastating
                      neurodegenerative disorder characterized by a selective loss
                      of striatal medium spiny projection neurons (MSNs).
                      Prodynorphin (PDYN) is enriched in a subpopulation of
                      striatal MSNs. Postmortem brains of HD patients and rodent
                      models have been demonstrated to have reduced levels of PDYN
                      transcripts and the neuropeptide dynorphin.Given the unmet
                      need for novel pharmacodynamic HD biomarkers in the context
                      of experimental huntingtin (htt)-lowering therapies, we
                      investigated the levels of PDYN-derived peptides and
                      neurofilament light (NfL) chain in the cerebrospinal fluid
                      (CSF) from HD patients (n = 16), matched controls (n = 55),
                      and patients with other neurodegenerative disorders (n =
                      70).PDYN-derived peptide levels were found to be
                      substantially decreased in HD patients (P < 0.0001 in
                      comparison to controls), whereas the NfL levels were
                      elevated in all neurodegenerative disorders.Our study
                      suggests decreased PDYN-derived peptide levels in the CSF as
                      a more specific biomarker for HD in comparison to NfL. ©
                      2020 The Authors. Movement Disorders published by Wiley
                      Periodicals LLC on behalf of International Parkinson and
                      Movement Disorder Society.},
      keywords     = {Corpus Striatum: metabolism / Enkephalins / Humans /
                      Huntingtin Protein / Huntington Disease / Neurofilament
                      Proteins / Peptides / Protein Precursors / neurofilaments;
                      prodynorphin; biomarker; Huntingtonʼs disease;
                      frontotemporal dementia (Other)},
      cin          = {Clinical Study Center Ulm},
      ddc          = {610},
      cid          = {I:(DE-2719)5000077},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33006791},
      doi          = {10.1002/mds.28300},
      url          = {https://pub.dzne.de/record/154327},
}